)
Overview
<ul>
<li>U.S. biopharmaceutical firm’s Q4 2025 revenue declined sharply yr/yr amid license suspension</li>
<li>Basic EPS for Q4 was -1.02, reflecting continued net losses</li>
<li>Company received $3.5 mln upfront license fee for HCW11-006 and launched two commercial-ready reagents</li>
</ul>
Outlook
<ul>
<li>Company says substantial doubt exists about ability to continue as going concern without additional funding</li>
<li>Company expects preliminary human data from HCW9302 Phase 1 trial in first half of 2026</li>
<li>Company plans to appeal Nasdaq notice on minimum bid price non-compliance</li>
</ul>
Result Drivers
<ul>
<li>LICENSE SUSPENSION - Revenue decline attributed to one-year suspension of Wugen license agreement, allowing co to market HCW9206 and HCW9201 as reagents</li>
<li>R&amp;D SPENDING - Q4 R&amp;D expenses increased 27% yr/yr, driven by ongoing clinical development activities</li>
<li>REAGENT LAUNCH - Co launched two proprietary fusion protein molecules as commercial-ready reagents to support cell-based immunotherapeutics production Company press release:</li>
</ul>
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q4 Basic -$1.02
<h3>EPS</h3>
Analyst Coverage
<ul>
<li>The one available analyst rating on the shares is “buy”</li>
<li>The average consensus recommendation for the biotechnology &amp; medical research peer group is “buy”</li>
<li>Wall Street’s median 12-month price target for HCW Biologics Inc is $2.00, about 454.2% above its March 30 closing price of $0.36 For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</li>
</ul>

IBBQ

SBIO

HCWB

LABU

Reuters

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

HCW Biologics

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

HCW Biologics Q4 revenue drops sharply on license suspension